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Summary
Background An alarming rise in reported Lassa fever cases continues in west Africa. Liberia has the largest reported 
per capita incidence of Lassa fever cases in the region, but genomic information on the circulating strains is scarce. 
The aim of this study was to substantially increase the available pool of data to help foster the generation of targeted 
diagnostics and therapeutics.
Methods Clinical serum samples collected from 17 positive Lassa fever cases originating from Liberia (16 cases) and 
Guinea (one case) within the past decade were processed at the Liberian Institute for Biomedical Research using a 
targeted-enrichment sequencing approach, producing 17 near-complete genomes. An additional 17 Lassa virus 
sequences (two from Guinea, seven from Liberia, four from Nigeria, and four from Sierra Leone) were generated 
from viral stocks at the US Centers for Disease Control and Prevention (Atlanta, GA) from samples originating from 
the Mano River Union (Guinea, Liberia, and Sierra Leone) region and Nigeria. Sequences were compared with 
existing Lassa virus genomes and published Lassa virus assays.
Findings The 23 new Liberian Lassa virus genomes grouped within two clades (IV.A and IV.B) and were genetically 
divergent from those circulating elsewhere in west Africa. A time-calibrated phylogeographic analysis incorporating 
the new genomes suggests Liberia was the entry point of Lassa virus into the Mano River Union region and estimates 
the introduction to have occurred between 300–350 years ago. A high level of diversity exists between the Liberian 
Lassa virus genomes. Nucleotide percent difference between Liberian Lassa virus genomes ranged up to 27% in the 
L segment and 18% in the S segment. The commonly used Lassa Josiah-MGB assay was up to 25% divergent across 
the target sites when aligned to the Liberian Lassa virus genomes.
Interpretation The large amount of novel genomic diversity of Lassa virus observed in the Liberian cases emphasises 
the need to match deployed diagnostic capabilities with locally circulating strains and underscores the importance of 
evaluating cross-lineage protection in the development of vaccines and therapeutics.
Funding Defense Biological Product Assurance Office of the US Department of Defense and the Armed Forces Health 
Surveillance Branch and its Global Emerging Infections Surveillance and Response Section.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Lassa fever is a haemorrhagic disease caused by Lassa 
virus, a member of the Mammarenavirus genus in the 
family Arenaviridae. Lassa virus was first discovered in 
Nigeria in 19691 and later detected in Liberia in 1972.2 
Historical evidence and molecular dating indicate that 
Lassa virus has circulated in west Africa for hundreds of 
years.3 The majority of the confirmed cases are from 
the Mano River Union region (Guinea, Liberia, and 
Sierra Leone) and Nigeria, but there is evidence of Lassa 
virus in Benin, Burkina Faso, Ghana, Côte d’Ivoire, Mali, 
and Togo.4
An estimated 300 000 infections of Lassa fever occur 
annually, resulting in approximately 5000 deaths.4 For 
approximately 80% of these cases, symptoms are mild 
and undiagnosed.4 In the other 20% of infections, 
common symptoms include back and chest pain, facial 
swelling, haemorrhaging, respiratory distress, and 
vomiting.4 The estimated fatality rate for all Lassa fever 
infections is 1%, with a 15–20% case fatality rate in 
patients who are admitted to hospital.4 Because of the 
lack of standardised surveillance programmes, these 
numbers are all estimates and may not be an accurate 
representation of the true burden of Lassa fever in 
west Africa. Standardisation of surveillance has been 
complicated by the non-specific symptoms of Lassa fever, 
the high level of nucleotide (20–25%) and amino acid 
(8–12%) diversity within Lassa virus, and an overall lack 
of access to care for a large percentage of the population 
in endemic areas, resulting in a majority of clinical cases 
going undiagnosed.4–6
To address the lack of effective diagnostics, public 
and private groups have started addressing the gaps. 
Immunoassays have been developed to detect anti-Lassa 
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virus IgM, IgG, and Lassa virus antigen, and these 
immunoassays have been converted into rapid diagnostic 
tests that are pan-Lassa, cheap, and transportable.6,7 
However, diagnostic tests labelled "for research use only" 
are the only ones that have been made commercially 
available to all countries. Typically, immunoassays are 
not as sensitive as PCR-based tests, and severe infections 
can suppress the production of IgM and IgG and cause 
false-negative results.7 A recent study in Sierra Leone did 
show greater sensitivity of immunoassays based on Lassa 
virus antigen compared with the PCR-based tests that 
were being used.8 Molecular diagnostic tests are 
considered the most sensitive method, but can produce 
false-negative results due to the high degree of genetic 
diversity. There are commercially available assays 
from three different vendors that have the CE IVD 
determination from EU regulators. An appropriate 
diagnostic algorithm will require a combination approach 
of serological and molecular diagnostics to capture the 
wide range of Lassa virus diversity that can be present in 
a given country. Reviews of currently available serological 
and molecular based diagnostics have been published. 6,7
In 2018, Nigeria had an increase in Lassa fever cases 
associated with a case fatality rate of approximately 25%, 
causing concern in the global public health community.9,10 
Genomic analysis of the circulating strains compared with 
historical data indicated that the rise in cases was not 
caused by a new circulating variant or sustained human-to-
human transmission, but that it was consistent with 
transmission from the rodent reservoir.9,10 During the 
same period, Liberia also had a seasonal outbreak of Lassa 
fever. Despite the long history of Lassa virus in Liberia,2 a 
history of exported cases,11,12 and the high per capita rate of 
reported cases (table 1), little is known about the viral 
genetic diversity circulating in this country. We report 
17 Lassa virus genome sequences from clinical cases 
(one from Guinea and 16 from Liberia) and 17 from viral 
stocks (two from Guinea, seven from Liberia, four from 
Nigeria, and four from Sierra Leone). We used these 
genomes to infer the evolutionary history of Lassa virus in 
Liberia and more broadly in west Africa, and investigated 
the appropriateness of current sequence-based diagnostic 
tools for detecting Lassa virus lineages from Liberia.
Methods
Sample processing and sequencing
De-identified human serum samples obtained from 
patients determined to be positive for Lassa fever by the 
Liberian National Reference Laboratory were processed 
for sequencing at the Liberian Institute for Biomedical 
Research. Accompanying metadata were provided by the 
National Public Health Institute of Liberia (ethics 
statement is provided in the appendix, p 3). Samples in 
Liberia were sequenced on an Illumina MiSeq at the 
Liberian Institute for Biomedical Research using an 
enrichment-based method as previously described13 with 
modifications to enrich Lassa virus. Archival isolates at 
the US Center for Disease Control and Prevention (CDC) 
Viral Special Pathogens branch in Atlanta, GA, were 
sequenced using the TruSeq Stranded mRNA kit on an 
Illumina MiniSeq. Additional details on sequencing 
methods can be found in the appendix (p 3). The 
consensus genome sequences were deposited in 
GenBank (appendix p 6).
Phylogenetics and molecular clock analysis
We generated Large (L) and Small (S) segment-level coding 
sequence alignments (concatenated open reading frames) 
Research in context
Evidence before this study
Genomic sequencing of epidemics is becoming a powerful tool 
to investigate outbreaks, reservoir jumps, and transmission. 
Additionally, genomic characterisation enables identification 
of possible target erosion in diagnostic assays, informs 
countermeasures development including vaccines, and informs 
molecular epidemiology tracing of outbreaks. We searched 
PubMed without language restrictions in March, 2019, for 
articles using the terms “Lassa,” “LASV” or “Lassa virus” with 
the terms “genomic epidemiology,” “diagnostic,” “epidemic or 
endemic” or “Liberia”. Although numerous previous studies 
were discovered, only 59 articles were identified when using 
both “Lassa” and “Liberia” terms in the search and most of 
these only mentioned Lassa virus in the introduction, 
while the main topic of the paper was on another pathogen.
Added value of this study
We obtained 23 near-complete Lassa virus genomes from 
Liberia. This represents a ten-fold increase compared with the 
two coding-complete genomes currently found on GenBank. 
The new genomes span both temporally (1972–2017) 
and spatially (Bong, Nimba, Montserrado, and Lofa counties) 
across Liberia. Our data indicate that the Liberian Lassa virus 
strains are distinct from those circulating elsewhere and that 
improved molecular diagnostics are needed to detect Lassa 
fever more effectively in Liberia.
Implications of all the available evidence
The large genomic diversity of Lassa virus emphasises the 
need to match deployed diagnostics capabilities with locally 
circulating strains and underlines the importance of 
evaluating cross-lineage protection in the development 
of vaccines and therapeutics. The data also highlight the 
need to increase Lassa fever surveillance using appropriate 
diagnostics, and to implement strategies that can cope with 
high levels of diversity.
See Online for appenidx
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in Geneious (version 11.1.4; Biomatters, Auckland, 
New Zealand) using publicly available sequences covering 
at least 80% of the protein-coding portions of either the 
L or S genome segment. Maximum-likelihood phylogenies 
were generated using RAxML Next Generation with the 
GTR+G4 model and 100 bootstrap replicates.14 Root-to-tip 
distances using the same dataset were generated with 
TempEst (v1.5.1)15 using the best-fitting root option. 
Bayesian phylogenies for each of the segment-level 
alignments were generated in BEAST (v1.8.4).16 Detailed 
methods for the analysis and model comparisons are 
provided in the appendix (pp 3–4, p 7).
Lassa virus PCR assay evaluation
Lassa virus specific PCR assays were evaluated using 
both in vitro and in silico methods. The in vitro analysis 
was done using the two assays deployed in Liberia, the 
Nikisins17 and Trombley Josiah-MGB.18 The in silico 
analysis was done with the PCR Signature Erosion 
Tool (version 1)19 using 16 published Lassa virus assays, 
including the Nikisins and Trombley Josiah-MGB. 
A final in silico analysis was done by aligning the PCR 
primers and probes to all the available Lassa virus 
sequences and measuring the number of mismatches 
(appendix p 8, pp 12–21, p 24). A more detailed 
description of the assay evaluation can be found in the 
appendix (p 4).
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Serum samples positive for Lassa virus were provided by 
the National Public Health Institute of Liberia and were 
processed and sequenced at the Liberian Institute for 
Biomedical Research. We sequenced six samples from 
2018 (one was an imported case from Guinea) and 
11 archival samples collected between 2011 and 2017 
(table 2). Most samples originated from known Lassa 
fever hotspots in Bong and Nimba counties. Cases from 
Montserrado county probably represent imported cases 
from endemic counties—for instance, the patient of 
sample LIB-LF17-001 was a resident of Ganta in Nimba 
county who became febrile in Montserrado. Coding-
complete genomes were obtained for 12 samples; the 
remaining five had gaps in coverage in the L protein 
(appendix p 6). We generated 17 coding-complete 
sequences from viral stocks of historical reference 
samples (two from Guinea, seven from Liberia, four 
from Nigeria, and four from Sierra Leone), from the 
Centers for Disease Control Viral Special Pathogens 
Branch (CDC-VSPB) as well. Of the seven samples 
originating from Liberia, three were imported into 
the USA with clear epidemiological links to Liberia.11,12 
Pairwise comparisons of the new coding-complete 
Liberian genomes showed nucleotide diversity that 
ranged up to 27% in the L segment and 18% in the 
S segment.
Segment-level phylogenetic analysis, including publicly 
available Lassa virus genomes, indicated that all of our 
Liberian genomes belong to lineage IV (figure 1).20,21 
The only exception was the L segment from isolate 
807978-P28, which falls outside of the diversity previously 
characterised for lineage IV (appendix p 22). The Liberian 
Lassa virus genomes are split between two major 
clades within lineage IV (labelled IV.A and IV.B in the 
2014 2015 2016 2017 2018
Liberia
Reported cases 10 3 96 81 191
Confirmed cases 1 0 14 30 21
Confirmation rate 10·0% 0 14·6% 37·0% 11·0%
Population size (million) 4·39 4·50 4·61 4·73 4·85
Reported per 100 000 0·23 0·07 2·08 1·71 3·94
Confirmed per 100 000 0·02 0·00 0·30 0·63 0·43
Nigeria
Reported cases 929 430 901 1022 3276
Confirmed cases 110 25 101 308 588
Confirmation rate 11·8% 5·8% 11·2% 30·1% 17·9%
Population size (million) 176·46 181·18 185·99 190·87 195·88
Reported per 100 000 0·53 0·24 0·48 0·54 1·67
Confirmed per 100 000 0·06 0·01 0·05 0·16 0·30
2014 and 2015 had known under-reporting in Liberia due to the Ebola virus disease outbreak. Case numbers for Liberia were obtained from the Liberian Ministry of Health 
(personal communication) and the Liberia IDSR Epidemiology Bulletin. Case numbers for Nigeria obtained from Nigeria Centre for Disease Control weekly Lassa update 
reports. Population data were obtained from Worldometers on Feb 14–19, 2019.
Table 1: Lassa fever cases in Liberia and Nigeria, 2014–18
For the Liberia IDSR 
Epidemiology Bulletin see 
https://nationalphil.org
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L and S genome segment trees of figures 1 and 2). The 
genome segments from the 2018 imported case from 
Guinea grouped into clade IV.A which, until now, only 
contained partial S genome segments of Liberian origin 
(appendix p 23). Clade IV.B had been observed in Guinea, 
Liberia, and Sierra Leone and contains the two previously 
available coding-complete genomes from Liberia. We 
estimated that these two clades diverged approximately 
300–350 years ago (L: median 1669, 95% highest posterior 
density [HPD] interval 1616–1717]; S: median 1720, 
95% HPD interval 1674–1758) by fitting a molecular 
clock to the data. Notably, the Liberian isolate 
807978-P28 appears to be a reassortant, with an S segment 
from clade IV.A and an L segment that does not fall 
within lineage IV or V but belongs to a previously 
unobserved phylogenetic lineage (appendix pp 22–23). 
A more detailed analysis below the lineage level is 
provided in the appendix (pp 4–5).
Our molecular clock analysis of lineages IV and V 
estimated substitution rates (L: 8·4 × 10–⁴ substitutions 
per site per year, 95% HPD interval 7·6 × 10–⁴ to 9·2 × 10–⁴; 
S: 8·2 × 10–⁴, 95% HPD interval 7·2 × 10–⁴ to 9·1 × 10–⁴) that 
are consistent with previous studies3,21 that included all 
five Lassa virus lineages. Our estimates for the time of 
most recent common ancestors (tMRCA) for the large 
clade from Sierra Leone in lineage IV and lineage V 
(figure 2A and 2B) are in line with previous estimates of 
about 150 years ago.3,21 However, new genomes from 
Liberia and Guinea have pushed back estimates for the 
introduction of Lassa virus into the Mano River Union 
from about 220 to 300–350 years ago (figure 2A and 2B).3 
Both S-based and L-based segment estimates were highly 
consistent. Our analysis indicated that with the current 
data, Liberia was most likely the entry point for Lassa 
virus to the Mano River Union (posterior probability 
≥94%), and that the virus was later introduced, at least 
four times, into Guinea (0–40, 40–60, 50–130, and 
90–280 years ago) and at least once into Sierra Leone 
(about 150 years ago; figure 2A and 2B). Root-to-tip 
distances were also generated using the identical dataset 
and a positive correlation between sampling date and 
root-to-tip distance is observed, indicative of molecular 
clock signal in the data (figure 2C and 2D).
Liberia was identified as the most likely location for the 
MRCA of lineages IV and V, although the low posterior 
support indicates ambiguity in this assignment with the 
current dataset. Although the S and L segment trees were 
highly consistent, they differed substantially in their 
tMRCA estimates for the ancestor of lineages IV and V. 
This is likely due to the L segment of isolate 807978-P28, 
which, as mentioned previously, is consistent with a 
reassortment event and does not belong to either lineage 
IV or V. Evidence for an additional sequence outside of 
lineage IV and V is present in the S genome segment 
phylogeny after inclusion of the partial genomes 
(appendix p 23). These results suggest that the genetic 
diversity of Lassa virus remains undersampled. Thus, 
these tMRCAs will likely need further revision with the 
addition of more sequence data.
The Liberian National Reference Laboratory in Charles- 
ville uses two quantitative real-time PCRs (rtPCRs) assays 
to detect Lassa virus: the Lassa Josiah-MGB assay (which 
was designed to detect the lineage IV and targets the 
glycoprotein precursor [GPC] gene on the S genome 
Country County or prefecture District of residence Health-care facility Specimen type Collection date
LIB-LF11-003 Liberia Bong Suakoko Phebe Hospital Serum Feb 20, 2011
LIB-LF11-011 Liberia Bong Jorkoqulleh Phebe Hospital Serum April 14, 2011
LIB-LF13-006 Liberia Nimba Seclepea Mah Seclepea Health Center Serum April 29, 2013
LIB-LF13-007 Liberia Nimba Seclepea Mah Seclepea Health Center Serum April 29, 2013
LIB-LF16-004 Liberia Bong Jorkoqulleh Phebe Hospital Serum Feb 26, 2016
LIB-LF16-016 Liberia Nimba Garr Bain Ganta United Methodist Hospital Serum April 13, 2016
LIB-LF17-001 Liberia Montserrado* Ganta Ganta United Methodist Hospital Serum Jan 9, 2017
LIB-LF17-007 Liberia Nimba Seclepea Mah Ganta United Methodist Hospital Serum Jan 9, 2017
LIB-LF17-013 Liberia Bong Jorkoqulleh Phebe Hospital Serum Feb 13, 2017
LIB-LF17-019 Liberia Bong Jorkoqulleh Phebe Hospital Serum May 4, 2017
LIB-LF17-020 Liberia Nimba Seclepea Mah Phebe Hospital Serum May 2, 2017
LIB-LF18-001 Liberia Bong NA NA Serum Jan 10, 2018
LIB-LF18-002 Guinea Yomou NA Diécké Serum Jan 10, 2018
LIB-LF18-037 Liberia Nimba NA NA Serum Feb 13, 2018
LIB-LF18-040 Liberia Montserrado NA NA Serum March 2, 2018
LIB-LF18-041 Liberia Montserrado NA NA Serum March 3, 2018
LIB-LF18-042 Liberia Nimba NA NA Serum March 1, 2018
Samples were provided by the National Public Health Institute of Liberia and were processed and sequenced at the Liberian Institute for Biomedical Research. Country, 
county, and prefecture indicate where the patient first presented with symptoms and district of residence indicates where the patient lives. NA=not available. 
*Patient was in Montserrado county when becoming febrile but suspected to have become infected in Nimba county.
Table 2: Clinical serum samples positive for Lassa virus collected from Liberia and Guinea
Articles
www.thelancet.com/infection   Vol 19   December 2019 1375
segment)18 and the La-V assay (designated Nikisins, which 
was designed to be a pan-Lassa assay and targets the RNA-
dependent RNA polymerase [L] gene on the L genome 
segment).17 Samples analysed at the Liberian National 
Reference Laboratory revealed a large number of 
discrepancies between the results of the two assays; the 
Nikisins assay often produced positive results for samples 
for which the Lassa Josiah-MGB was negative. We aligned 
the primers and probes from the two assays to the newly 
sequenced Lassa virus genomes and observed a large 
number of mismatches in the target sites of the Lassa 
Josiah-MGB assay (75·0–98·4% identity across target sites, 
as seen in appendix p 24). Fewer mismatches were present 
in the targeted regions of the Nikisins assay (94·6–100% 
identity across target sites), mainly due to well-placed 
ambiguous bases to account for Lassa virus diversity.
To determine how these mismatches would affect the 
ability to detect Lassa virus using the Nikisins or Lassa 
Josiah-MGB assays, we did in vitro tests using 16 viral 
stocks that originated from west Africa (appendix p 9). 
Figure 1: Maximum-likelihood trees for Lassa virus L and S genome segments sequenced from human infections and reservoir hosts in west Africa
(A) Maximum-likelihood tree for L genome segment. (B) Maximum-likelihood tree for S genome segment. Nodes are coloured based on the country of origin. 
Sequences generated from the 2018 cases are outlined in red (see table 2 and appendix p 6 for sample metadata and sequence completeness), other sequences from 
this study are outlined in black. For the collapsed clades, the number of contained sequences is specified. Scale bars indicate number of nucleotide substitutions per site. 
Roman numerals are used to label previously defined Lassa virus lineages20,21 (see appendix pp 22–23 for subtrees of lineage IV and V which include partial sequences). 
The heatmaps to the right of the phylogenetic trees in panels A and B represent the percent identity of the assay target site as presented in the appendix (pp 12–21). 
The numbers above the heatmap in panel A represent the following assays: 1 Nikisins22 and 2 Vieth.17 The numbers above the heatmap in panel B represent the 
following assays: 1 Bowen,20 2 Coulibaly,23 3 Demby,24 4 Leski,25 5 Olschläger,26 and 6 Safronetz27 (see appendix p 8 for assay sequences and the gene targets).
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Four ten-fold dilutions of each viral stock were tested to 
see if either assay could detect all the dilutions. The 
Nikisins assay was able to detect all the Liberian isolates 
at every dilution; however, the Josiah-MGB assay was 
only able to detect two of the seven Liberian isolates at all 
four dilutions. A correlation was observed between the 
1980
R2=0·07
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Figure 2: Temporal maximum 
clade credibility trees for 
Lassa virus L and S genome 
segments sequenced from 
human infections and 
reservoir hosts in west Africa
(A) Temporal maximum clade 
credibility tree for L genome 
segment. (B) Temporal 
maximum clade credibility tree 
for S genome segment. 
Only lineages IV and V were 
included in this analysis. 
Small black circles indicate 
clades with posterior 
probabilities of at least 90%. 
Branches are coloured 
according to the inferred 
ancestral location of each 
lineage. Coloured rings 
indicate nodes with ancestral 
state posterior probabilities of 
at least 90%; nodes below this 
threshold are labelled with 
their respective probabilities. 
The grey violin plots represent 
the 95% highest posterior 
density intervals for the time 
of most recent common 
ancestor (tMRCA) for clades 
IV.A, IV.B, lineage IV, and 
lineages IV and V together 
(tree root). Liberian samples 
with known county of origin 
are indicated with filled circles 
and coloured according to 
county of origin. Since the 
L genome segment of sample 
807978-P28 fell outside of the 
diversity previous described 
for lineages IV it was not used 
in the tMRCA analysis for this 
lineage. (C) Root-to-tip 
distances for the L genome 
segment. (D) Root-to-tip 
distances for the S genome 
segment. Colours indicate 
country of origin and the line 
represents a simple linear 
regression (see appendix p 7 
for the BEAST model 
comparison for the 
L and S genome segments).
Articles
www.thelancet.com/infection   Vol 19   December 2019 1377
number of mismatches in the target region and ability to 
detect all dilutions.
Because of the discrepancies observed between the Lassa 
Josiah-MGB assay and the Nikisins assay, we expanded our 
evaluation to other published Lassa virus rtPCR assays 
using in silico methods. The goal was to quickly evaluate 
alternatives for detection of Lassa virus in Liberia and 
other endemic regions in Africa. We evaluated 16 published 
assays with the PCR Signature Erosion Tool (appendix p 10) 
by calculating the percent identity across the target regions 
and inferring the minimal number of assays needed to 
cover all the diversity in the L and S segment (appendix p 11). 
We listed the percent identities of the two L segment assays 
and the top six S segment assays along with accession 
numbers (appendix pp 12–22) and presented the data as a 
heatmap in figure 1 to coordinate with the tips of the 
phylogenetic tree. Among the two published L segment 
assays tested, the Nikisins assay showed the highest 
percent identity across the target site of the analysed Lassa 
virus genomes, with a range of 94·6–100% and an average 
of 98·6% (figure 1; appendix pp 12–22). Between the six 
S segment assays tested, the Bowen20 and Coulibaly23 
assays had the highest average identity at 95·2% for Bowen 
and 96·1% for Coulibaly (appendix pp 12–22). When 
focusing on just genomes of Liberian origin, the Ölschläger 
assay26 had the highest average identity for an S segment 
assay at 94·2%.
Discussion
Liberian Lassa virus genomes are substantially under- 
represented in genomic databases by comparison with 
other Mano River Union countries and Nigeria. As of 
January, 2019, only two coding-complete Lassa virus 
genomes, 36 partial S genome segments (27 GPC 
at 60–80% coverage and nine nucleoprotein at 
40% coverage), and six partial L genome segments (6–12% 
coverage of L gene) of Liberian origin were available on 
GenBank. The short sequence length limits the type of 
downstream analyses that can be done compared with 
coding-complete genomes. To address the scarcity of 
genetic information, we obtained coding-complete viral 
genomes from confirmed cases during the 2018 Lassa 
fever season and from a collection of archival samples. In 
total, we were able to generate 34 near-complete genomes 
for the L and S segments, 23 of these coming from samples 
of Liberian origin (figure 1; table 2; appendix p 6).
These newly sequenced genomes show a large amount 
of diversity is present among circulating strains in Liberia. 
The genomes were grouped into two distinct and well-
supported clades, which we designated IV.A and IV.B. 
When geographical information was available, we found 
that the Liberian genomes grouped according to location 
rather than collection dates, which is consistent with 
previous observations in Guinea, Nigeria, and Sierra 
Leone.3,9,10,20,25,28 Most newly sequenced samples grouped in 
clade IV.A, which until now had only been represented in 
GenBank by partial genomes (figure 1; appendix pp 22–23). 
The Liberian genomes from clade IV.A originate from 
Bong, Montserrado, and Nimba counties, and could not be 
resolved further than county-level based on the available 
metadata. Clade IV.A could be split further into three well 
supported subclades that include a grouping of all three 
counties, a group of Bong and Montserrado counties, and 
a group of just Nimba county. The imported 2018 case 
from Guinea also grouped in clade IV.A, specifically in the 
subclade that included representatives from Bong, 
Montserrado, and Nimba. More details on the movement 
of Lassa fever between Liberia and Guinea can be found in 
the appendix (p 5).
Clade IV.B has been previously observed in Guinea, 
Liberia, and Sierra Leone, and both of the previously 
available coding-complete genomes from Liberia belong to 
this clade. The majority of Liberian genomes that belong to 
this clade are older (originating from 1972–81) and were 
isolated from patients diagnosed at Curran Lutheran 
Hospital in Zorzor, Liberia, in Lofa County.29,30 One of the 
2018 samples, LF18040, falls within a well-supported 
subclade of IV.B, which had not been detected for the past 
37 years (appendix pp 22–23), showing that this clade 
continues to circulate.
Even with additional sequencing data, it appears further 
sampling is still needed to capture all the Lassa virus 
diversity circulating in Liberia. Multiple indicators of this 
include the L and S genome segments of the previously 
reported G1200 strain (KM821797 and KM821798), which 
group only with sequences from Guinea and Sierra Leone, 
and the L segment of strain 807978-P28 and the partial 
S segment from the previously reported Lib05-4094 strain 
(GU830819), which both fall outside of lineage IV and V 
(appendix pp 22–23). The available metadata indicate that 
807978-P28 is from Bong country, but for G1200 and 
Lib05-4094 only the country of origin is provided, making 
it difficult to determine the region of the country in which 
this diversity is present. Additional Lassa virus surveillance 
and sequencing of confirmed cases is required to ensure 
that the complete viral diversity in Liberia has been 
covered.
To expand successful surveillance activities of Lassa fever 
in Liberia, deployed diagnostics need to detect all of the 
known genomic diversity. Reliance solely on sequence-
based assays can cause limitations as shown in a 
2015 international quality assessment study.17 In this study, 
Nikisins and colleagues17 observed 11 out of 24 international 
reference laboratories had at least one false-negative result 
and four of these laboratories did not identify any of the 
samples originating from Liberia.17 One solution would be 
to switch to multiple pan-Lassa assays that target the 
L and S segment (eg, Altona RealStar Nikisins assays), as 
done during the 2018 Lassa fever outbreak in Nigeria to 
help eliminate false-negative results due to potential target 
erosion.10 Another solution would be to incorporate 
immunoassays into the testing algorithms as has been 
shown in field testing in Sierra Leone.8 The rapid diagnostic 
antigen test was able to detect samples missed by the 
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rtPCR assay and new pan-Lassa rapid diagnostic tests 
could provide an even broader detection capacity.
The dramatic increase of Lassa fever cases in west Africa, 
including Liberia and Nigeria, highlights the growing risk 
Lassa virus poses to regional and global health security. 
The overwhelming amount of observed Lassa virus 
diversity underscores the requirement that medical 
countermeasures and diagnostic assays developed against 
commonly used Lassa virus laboratory strains are re-
evaluated locally to ensure effectiveness at preventing, 
detecting, and treating all the circulating strains. Our data 
identify concerns in the current molecular diagnostic 
assays being used in Liberia and highlight the need to 
evaluate more recently developed pan-Lassa rtPCR assays 
and rapid diagnostic tests in Liberia, to develop a more 
comprehensive testing algorithm. Our results are probably 
not unique to Liberia and emphasise that these problems 
might not be completely resolved if we focus too much on 
any given country or region.
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